Syrna Therapeutics
Del Mar, US · Founded 2020 · Delaware corporation · 1 known investors
Syrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
BiotechDeep Tech
Founders & leadership
TH
Thomas HermanninNamed on SEC filing
AA
Aiden AcevesNamed on SEC filing
DW
David WeitzinNamed on SEC filing
Board
JD
Investors · 1
Reported raises · per SEC filings
Form D private placements$10.9M disclosed across 1 round · 2023
▶$10.9MraisedAug 2023 · 3 investors · BiotechnologyRule 506(b)
▶$10.9MraisedAug 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas HermannDirector
- Aiden AcevesDirector
- Joel DudleyDirector
- David WeitzExecutive Officer, Director
- Offering amount
- $10.9M
- Amount sold
- $10.9M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Syrna Therapeutics went on to found or lead other companies.
Competitors · 7
by search overlapSionnatx30 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Sirnaomics28 shared keywordsSirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
Ronatherapeutics27 shared keywordsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.
Switch Therapeutics26 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Serna Bio23 shared keywordsSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Siriusrna22 shared keywordsSirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets. It applies RNA interference technology to create new treatment options for patients.
Bioworld16 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Syrna Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Syrna Therapeutics do?
- Syrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.
- Who are Syrna Therapeutics's investors?
- Syrna Therapeutics's investors include Innovation Endeavors.
- How much funding has Syrna Therapeutics raised?
- Syrna Therapeutics has disclosed $10.9M raised across 1 round.
- Where is Syrna Therapeutics headquartered?
- Syrna Therapeutics is headquartered in Del Mar, US.